Sutro Biopharma Inc
STRO0.900USD
+0.175+24.17%
Handelsschluss 04/23, 16:00（ET）Kurse um 15 Minuten verzögert
74.27MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sutro Biopharma Inc Unternehmen
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Unternehmensinformationen
Unternehmens-codeSTRO
Name des UnternehmensSutro Biopharma Inc
IPO-datumSep 27, 2018
Gegründet am2003
CEOMs. Jane Chung
Anzahl der mitarbeiter310
WertpapierartOrdinary Share
GeschäftsjahresendeSep 27
Addresse111 Oyster Point Blvd.
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16503928412
Websitehttps://www.sutrobio.com/
Unternehmens-codeSTRO
IPO-datumSep 27, 2018
Gegründet am2003
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sukhi Jagpal
Ms. Sukhi Jagpal
Director
Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Aktionärsstatistik
Aktionäre
Anteil
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Art
Aktionäre
Anteil
Hedge Fund
33.76%
Investment Advisor/Hedge Fund
24.76%
Investment Advisor
14.75%
Corporation
3.25%
Research Firm
3.03%
Venture Capital
2.86%
Individual Investor
1.15%
Pension Fund
0.46%
Bank and Trust
0.12%
Other
15.86%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
282
70.21M
83.81%
-8.43M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
2023Q1
320
58.55M
98.20%
-11.55M
2022Q4
332
54.70M
96.18%
-13.75M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Suvretta Capital Management, LLC
7.46M
8.91%
+275.00K
+3.83%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.29M
7.51%
+542.02K
+9.43%
Dec 31, 2024
RA Capital Management, LP
4.43M
5.29%
+4.43M
--
Mar 28, 2025
The Vanguard Group, Inc.
4.21M
5.02%
+13.43K
+0.32%
Dec 31, 2024
Kynam Capital Management LP
3.64M
4.35%
+1.57M
+76.22%
Dec 31, 2024
Merck & Co Inc
2.72M
3.25%
+2.72M
--
Dec 31, 2024
Vestal Point Capital, LP
2.57M
3.07%
+2.57M
--
Dec 31, 2024
Citadel Advisors LLC
2.46M
2.93%
+332.00K
+15.61%
Dec 31, 2024
Point72 Asset Management, L.P.
2.20M
2.62%
-799.91K
-26.69%
Dec 31, 2024
Samsara BioCapital, LLC
2.20M
2.62%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Range Cancer Immunotherapy ETF
0.76%
Invesco NASDAQ Future Gen 200 ETF
0.31%
ALPS Medical Breakthroughs ETF
0.11%
Avantis US Small Cap Equity ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Mehr Anzeigen
Range Cancer Immunotherapy ETF
Anteil0.76%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.31%
ALPS Medical Breakthroughs ETF
Anteil0.11%
Avantis US Small Cap Equity ETF
Anteil0.01%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
iShares Micro-Cap ETF
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
Fidelity Enhanced Small Cap ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten